The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
One key change would grant patents to the first inventor to file an application, not the first who can prove to have made
the invention first.
Roche Holding AG’s decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications
staff. Most of that staff is based in Indianapolis.
One-time events influenced bottom lines of some of the few companies that made more money in 2009.
Few escaped the Great Recession unscathed, and unusual circumstances helped some appear as though they did.
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
O’Connor, chief deputy mayor under former Indianapolis Mayor Bart Peterson, started Monday as Lilly's director of
state government affairs—working again under Peterson.
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine’s use to patients whose
disease is in an earlier stage.
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
Indianapolis-based Eli Lilly and Co. spent about $2.3 million in the first quarter of 2010 lobbying the federal government
on health care reform, Medicare reimbursement and trade issues among other topics.
Moody's Investors Service on Friday lowered its rating outlook on drugmaker Eli Lilly and Co. to "negative"
from "table" due in part to the looming expiration of patents protecting key drugs from generic competition.
The unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern
Asia.
The price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc. CEO David Snow said.
U.S. companies, including Eli Lilly, amassed at least $1 trillion in foreign profits not taxed in the U.S. as of the end of
last year. That cumulative total increased 70 percent over three years.
The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1
billion in annual expenses.
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco’s productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
